A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)

Xention

Status and phase: Completed; Phase 2; Phase 1

Conditions: Elevated Lp(a)

Treatments: Drug: TA-8995; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT02241772

TA-8995-06

Details and patient eligibility

About

A study in males and females with elevated Lp(a) to look at the effects of TA-8995 on Lp(a) levels.

Enrollment: 42 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male and female (of non-child bearing potential) subjects with elevated Lp(a) levels

Exclusion criteria

• Clinically significant medical history
• Abnormal laboratory results (other than lipid levels) or vital signs
• Receiving any other drug therapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

42 participants in 3 patient groups, including a placebo group

10mg TA-8995

Experimental group

Description:

10mg TA-8995 once daily

Treatment:

Drug: TA-8995

2.5mg TA-8995

Experimental group

Description:

2.5mg TA-8995 once daily

Treatment:

Drug: TA-8995

Placebo to TA-8995

Placebo Comparator group

Description:

Placebo to TA-8995 once daily.

Treatment:

Drug: Placebo